Neurotech International (ASX:NTI) has received Orphan Drug Designation from the European Commission for NTI164, its lead drug candidate for Rett Syndrome, a neurodevelopmental disorder, according to a Monday filing with the Australian bourse.
The designation grants market exclusivity, reduced regulatory fees, access to research funding, and protocol assistance, the filing said.
Shares of the firm rose past 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.